Astrocytoma, Glioblastoma, Venous Thromboembolism
Conditions
Keywords
High grade glioma, Glioblastoma, Astrocytoma, Venous thromboembolism, Apixaban
Brief summary
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
Detailed description
Patients with primary brain tumors, including glioblastoma and astrocytoma, are at high risk of developing venous thromboemboli (VTE) as a comorbid condition. Prior studies have demonstrated safety and efficacy of primary pharmacological prevention of VTE using blood thinning medications, including apixaban. These studies have included a small cohort of patients with grade 4 glioma. The purpose of this study is to gather additional safety data regarding the use of apixaban for primary prevention of VTE in patients with newly diagnosed grade 4 glioma.
Interventions
DRUGApixaban
Open label
Sponsors
University of Vermont Medical Center
Dartmouth-Hitchcock Medical Center
MaineHealth
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
Open label study of apixaban for VTE prevention in patients with newly diagnosed grade 4 glioma
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection. * Age 18 and old * Karnofsky performance status (KPS) 60-100 * Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25. * Ability to provide informed consent. * Planning for treatment with radiation and chemotherapy.
Exclusion criteria
* Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study. * Pregnancy. * Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial trauma in the past 6 months, including stroke or traumatic brain injury, major surgery or major procedure within 48 hours. * Allergy to apixaban or contraindication to prophylactic anticoagulation. Contraindications include patients who are currently on unfractionated heparin, low molecular weight heparin, heparin derivatives (examples: fondaparinux), or other direct oral anticoagulants (examples: dabigatran, edoxaban, rivaroxaban), who are either unable or unable to discontinue these agents in favor of the investigational drug. Apixaban is also contraindicated in patients who are on strong CYP3A4 inhibitor and P-glycoprotein inhibitors. * Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.). * Estimated life expectancy of \<3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of apixaban as determined by bleeding risk | 6 months | CTCAE 5 reporting of grade 2 non-Central Nervous System (CNS) hemorrhage or grade 2 new CNS hemorrhage. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy in prevention of venous thromboembolism | 6 months | Incidence of VTE |
Countries
United States
Contacts
CONTACTAlissa A Thomas, MD
CONTACTDonna Silver
PRINCIPAL_INVESTIGATORAlissa A Thomas, MD
University of Vermont Medical Center
Outcome results
None listed